Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
INVESTOR PRESENTATION - Biotron Limited
Health
Biotron Limited (BIT) is a biotechnology company engaged in research, development, and commercialisation of drugs targeting viral diseases with unmet medical need. The Company focuses on the progression of the clinical development of the drug, BIT225, an investigational, orally-administered, novel antiviral compound in development by Biotron for treatment of HCV and HIV infections.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
announcement | t+2 movement | date |
---|---|---|
| +1.19% | 19 Nov 2020 |
| +1.19% | 19 Nov 2020 |
| +1.19% | 29 Oct 2020 |
| +1.19% | 29 Oct 2020 |
| -1.04% | 14 Oct 2020 |
| -1.04% | 14 Oct 2020 |
| +2.22% | 08 Oct 2020 |
| -4.55% | 06 Sep 2020 |
| +15.79% | 03 Sep 2020 |
| +15.79% | 03 Sep 2020 |
Current Price
52WK HIGH
52WK LOW
1YR RETURN
1YR RETURN VS. SECTOR
90 DAY RETURN
ASX RANK
/2,047
SECTOR RANK
/168
SHARES OUTSTANDING
Health
Biotron Limited (BIT) is a biotechnology company engaged in research, development, and commercialisation of drugs targeting viral diseases with unmet medical need. The Company focuses on the progression of the clinical development of the drug, BIT225, an investigational, orally-administered, novel antiviral compound in development by Biotron for treatment of HCV and HIV infections.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
ASX:BIT is not raising right now
Want to invest?
(03) 9028 2888
clients@freshequities.com
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia